Therapeutic mRNA cancer vaccines
3 European H2020 organizations list this as part of their work — 2 as their primary capability.
Most active in this area
- ETHERNA IMMUNOTHERAPIES
Belgian biotech developing therapeutic mRNA cancer vaccines using proprietary TriMix platform, with clinical-stage programs in HPV-related cancers.
“TIGER and EXPERT both center on mRNA-based cancer therapeutics, with TIGER specifically advancing their TriMix mRNA vaccine platform through clinical trials.”
PrimarySMEBE3 projects - CERATIUM BV
Dutch biotech SME contributing to mRNA cancer vaccine clinical trials and photosynthesis-based crop improvement across European research consortia.
“TIGER (2021-2025) involves proof-of-principle development of a TriMix-based mRNA vaccine targeting HPV-associated cancers (cervical, head and neck, oropharyngeal) through Phase 1/2a trials.”
SMENL2 projects - SAGA DIAGNOSTICS AB
Swedish biotech SME developing circulating tumor DNA diagnostics and mRNA therapeutic vaccines for HPV-related cancers, with Phase 1/2a clinical experience.
“TIGER (2021–2025) targets proof-of-principle for an mRNA-based therapeutic cancer vaccine using the TriMix adjuvant platform across HPV-associated cancer indications.”
PrimarySMESE2 projects